NextCure (NXTC)
(Delayed Data from NSDQ)
$1.60 USD
-0.03 (-1.84%)
Updated Jul 23, 2024 04:00 PM ET
After-Market: $1.64 +0.04 (2.50%) 7:58 PM ET
3-Hold of 5 3
D Value D Growth D Momentum F VGM
Income Statements
Fiscal Year end for NextCure, Inc falls in the month of December .
All items in Millions except EPS data.
12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 | |
---|---|---|---|---|---|
Sales | 0 | 0 | 0 | 22 | 6 |
Cost Of Goods | 0 | 0 | 0 | 0 | 0 |
Gross Profit | 0 | 0 | 0 | 22 | 6 |
Selling & Adminstrative & Depr. & Amort Expenses | 68 | 76 | 71 | 64 | 44 |
Income After Depreciation & Amortization | -68 | -76 | -71 | -41 | -37 |
Non-Operating Income | 5 | 1 | 1 | 5 | 4 |
Interest Expense | 0 | 0 | 0 | 0 | 0 |
Pretax Income | -63 | -75 | -69 | -37 | -34 |
Income Taxes | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 |
Investment Gains/Losses | 0 | 0 | 0 | 0 | 0 |
Other Income/Charges | 0 | 0 | 0 | 0 | 0 |
Income From Cont. Operations | -63 | -75 | -69 | -37 | -34 |
Extras & Discontinued Operations | 0 | 0 | 0 | 0 | 0 |
Net Income (GAAP) | -63 | -75 | -69 | -37 | -34 |
Depreciation Footnote | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Income Before Depreciation & Amortization | -65 | -69 | -64 | -38 | -35 |
Depreciation & Amortization (Cash Flow) | 3 | 7 | 7 | 3 | 3 |
Income After Depreciation & Amortization | -68 | -76 | -71 | -41 | -37 |
Earnings Per Share Data | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Average Shares | 27.84 | 27.74 | 27.62 | 27.53 | 15.70 |
Diluted EPS Before Non-Recurring Items | -2.25 | -2.69 | -2.51 | -1.33 | -2.15 |
Diluted Net EPS (GAAP) | -2.25 | -2.69 | -2.51 | -1.33 | -2.15 |
Fiscal Year end for NextCure, Inc falls in the month of December .
All items in Millions except EPS data.
6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | |
---|---|---|---|---|---|
Sales | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Cost Of Goods | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Gross Profit | NA | 0.00 | 0.00 | 0.00 | 0.00 |
SG&A, R&D, and Dept/Amort Expenses | 0.00 | 18.31 | 15.79 | 15.62 | 19.16 |
Income After SG&A, R&D, and Dept/Amort Expenses | 0.00 | -18.31 | -15.79 | -15.62 | -19.16 |
Non-Operating Income | NA | 1.20 | 1.32 | 1.32 | 1.30 |
Interest Expense | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Pretax Income | NA | -17.11 | -14.47 | -14.30 | -17.86 |
Income Taxes | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Minority Interest | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Investment Gains/Losses | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Other Income/Charges | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Income From Cont. Operations | NA | -17.11 | -14.47 | -14.30 | -17.86 |
Extras & Discontinued Operations | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Net Income (GAAP) | NA | -17.11 | -14.47 | -14.30 | -17.86 |
Earnings Per Share Data | 6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 |
---|---|---|---|---|---|
Average Shares | NA | 27.90 | 27.91 | 27.84 | 27.83 |
Diluted EPS Before Non-Recurring Items | NA | -0.61 | -0.52 | -0.51 | -0.64 |
Diluted Net EPS (GAAP) | NA | -0.61 | -0.52 | -0.51 | -0.64 |